Keywords (1)

Academic
Publications
Phase I Safety, Pharmacokinetics and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

Phase I Safety, Pharmacokinetics and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors,10.1158/1078-0432.CCR-10-0748,Clini

Phase I Safety, Pharmacokinetics and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors   (Citations: 3)
BibTex | RIS | RefWorks Download
J. Baselga, A. Cervantes, E. Martinelli, I. Chirivella, K. Hoekman, H. I. Hurwitz, D. Jodrell, P. Hamberg, E. Casado, P. Elvin, A. Swaisland, R. Iaconahttp://academic.research.microsoft.com/io.ashx?type=5&id=31713800&selfId1=0&selfId2=0&maxNumber=12&query=
Journal: Clinical Cancer Research - CLIN CANCER RES , vol. 16, no. 17, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...Src inhibitors as potential therapeutic agents for use in bone-related diseases associated with breast cancer (Table 1). For example, saracatinib (AZD0530; Astra-Zeneca), a dual inhibitor of Src/Abl, has been shown to decrease levels of bone resorption markers in a phase I study in patients with solid tumors [23]...

    Philippe Clézardin. Therapeutic targets for bone metastases in breast cancer

    • ...The phase I study confirmed that tumor Src kinase activity was reduced following treatment with saracatinib [18]...
    • ...Compared to patients treated at the 175 mg dose level in the phase I study [18] and data from the phase II trial [23] investigating saracatinib in patients with prostate cancer, toxicity rates generally appeared higher in our patient population...
    • ...There did, however, appear to be less nausea and thrombocytopenia [18]...
    • ...These reached pre defined levels in four out of seven patients treated at the 175 mg dose level [18]...

    Helen J. Mackayet al. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in ...

Sort by: